Corvus Pharmaceuticals, Inc. (CRVS) Stock: Price, Forecast & Analyst Target
Corvus Pharmaceuticals, Inc. (CRVS) — MoonshotScore 57/100 (Fair band), calculated Nov 18, 2026. Price $10.01 (-1.77%), as of the Nov 19, 2026 trading session; market cap $844M.
Educational signal · not a buy or sell recommendation · How to read this
Corvus Pharmaceuticals, Inc. · CRVS · NASDAQ
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company specializing in the development of immuno-oncology therapies.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Corvus Pharmaceuticals (CRVS)
FairWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
A fortress balance sheet, but stalling growth and a full valuation. Business Quality: Average; Financial Safety: Fortress; Valuation: Full; Growth Durability: Shrinking; Momentum: Quiet.
- EPS beat 2 of the last 8 reports
- Altman Z 31.69 · Piotroski F 2
- ROE -35.0% · ROA -28.7% · current ratio 13.38 · earnings yield -6.5% · free-cash-flow yield -5.3%
Holding back: soft growth
Helping: balance-sheet strength
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 59 | Fair | |
| 61 | Fair | |
| 59 | Fair | |
| 59 | Fair | |
| 57 | Fair | |
| 57 | Fair |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $10.01 | |
| Change on the day | -1.77% | |
| 52-week range | $6.39 – $26.95 | |
| Market capitalisation | $844M | — |
| Price / earnings (trailing) | -16.88 | |
| Shares traded on the day | 705.5K |
Price & events
Other perspectives
Council score for Corvus Pharmaceuticals (CRVS): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 2, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 9, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Corvus Pharmaceuticals (CRVS), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Corvus Pharmaceuticals, Inc. (CRVS) is listed on NASDAQ. It employs 37 people and is led by Richard A. Miller. The market values it at $844M.
What do the latest results show for Corvus Pharmaceuticals (CRVS)?
Short answer · as of
Against analyst estimates the company has EPS beat 2 of the last 8 reports.
What are the financial strengths and risks for Corvus Pharmaceuticals (CRVS)?
Short answer · as of
The MoonshotScore pillars rate balance-sheet strength as strengths. What is holding it back is soft growth. The distress and quality screens read Altman Z 31.69 · Piotroski F 2. Trailing ratios: ROE -35.0% · ROA -28.7% · current ratio 13.38 · earnings yield -6.5% · free-cash-flow yield -5.3%.
Data-derived red flags
- Negative return on equity (-35.0%) — the business is not currently generating profit on shareholder capital.
- Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
What should you watch next at Corvus Pharmaceuticals (CRVS)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $1.18M · EPS -0.81 · 5 analysts. Current published price targets run low $27.00 · high $27.00 · consensus $27.00 · median $27.00 against a quoted price of $10.01 (as of Nov 19, 2026).
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- No quarterly income statement is held for CRVS.
Checked against the records this page reads, on the dates shown above.
How does Corvus Pharmaceuticals compare with its peers?
Short answer
Corvus Pharmaceuticals's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $18.40 Nov 18, 2026 | $1.31B | 96 5-pillar Nov 18, 2026 | |
| $945.53 Nov 18, 2026 | $97.8B | 95 5-pillar Nov 18, 2026 | |
| $9.07 Nov 19, 2026 | $540M | 91 5-pillar Nov 18, 2026 | |
| $42.53 Nov 18, 2026 | $801M | 88 5-pillar Nov 18, 2026 | |
| $58.34 Nov 19, 2026 | $119B | 85 5-pillar Nov 18, 2026 | |
| $47.40 Nov 19, 2026 | $1.41B | 76 5-pillar Nov 18, 2026 | |
| $137.78 Nov 18, 2026 | $340B | 69 5-pillar Nov 18, 2026 | |
| $12.17 Nov 19, 2026 | $861M | 69 5-pillar Nov 18, 2026 | |
| $40.04 Nov 19, 2026 | $1.30B | 69 5-pillar Nov 18, 2026 | |
| $9.28 Nov 19, 2026 | $545M | 68 5-pillar Nov 18, 2026 | |
| $18.52 Nov 19, 2026 | $1.14B | 66 5-pillar Nov 18, 2026 | |
| $30.78 Nov 19, 2026 | $1.03B | 64 5-pillar Nov 18, 2026 | |
| Corvus Pharmaceuticals (CRVS) — this page | $10.01 | $844M | 57 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $27.00 – $27.00
- Consensus target
- $27.00
- Median target
- $27.00
- Revenue estimate
- $1.18M
- EPS estimate
- $-0.81
Consensus record · Captured .
Measured against a quoted price of $10.01 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Jun 11, 2026
- Transactions
- 6
- Identified insiders
- 5
- Purchases
- 1
- Sales
- 0
- Other transactions
- 5
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held CRVS in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported CRVS in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Corvus Pharmaceuticals (CRVS)?
- Corvus Pharmaceuticals Schedules Third Quarter 2026 Financial Results and Business Update
- Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2026 Financial Results on November 5, 2026
- Corvus Pharma Q2 2026 Earnings Call Transcript
- Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Gap Up – Still a Buy?
Investor Questions: CRVS Stock
These answers are editorial: 1 of these 9 answers is drawn from the CRVS research dossier (written May 10, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for CRVS?
CRVS carries the MoonshotScore stated above — the Fair band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is CRVS a good stock to buy?
Stock Expert AI does not rate CRVS buy, sell or hold. Corvus Pharmaceuticals, Inc. carries a MoonshotScore, in the Fair band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the CRVS stock price today?
The last price recorded for Corvus Pharmaceuticals, Inc. (CRVS), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the CRVS price target?
The analyst consensus price target for Corvus Pharmaceuticals, Inc. (CRVS), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What do analysts say about CRVS stock?
Analyst coverage of Corvus Pharmaceuticals reflects a focus on its clinical pipeline and potential for future growth. Key valuation metrics include price targets based on the projected success of Mupadolimab and other pipeline assets.
What are the key factors to evaluate for CRVS?
Corvus Pharmaceuticals, Inc. (CRVS) holds a MoonshotScore in the moderate range. To weigh it, read the analyst view under Analyst targets & estimates on this page. Strategic collaboration with Angel Pharmaceuticals to develop its pipeline of targeted investigational medicines. Not financial advice.
How frequently does CRVS data refresh on this page?
CRVS's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven CRVS's recent stock price performance?
Corvus Pharmaceuticals, Inc. (CRVS) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Promising pipeline of clinical-stage immuno-oncology assets. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CRVS overvalued or undervalued right now?
Corvus Pharmaceuticals, Inc. (CRVS) is loss-making, so its trailing P/E (listed under Price & valuation) is negative and not usable for valuation — lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 21 figures on this page — 10 from Financial Modeling Prep (FMP), 10 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com